Accessibility StatementSkip Navigation Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.) SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 17, 2025 /PRNewswire/ -- Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics, Triclonics and ADClonics), and Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme"), a leader in subcuta ...

Financial Performance - Royalty revenue increased 52% year-over-year to a record $236 million, driving total revenue to a record $354 million, representing a 22% increase year-over-year [1][3][13] - Net income rose 28% year-over-year to $175 million, with adjusted EBITDA increasing 35% year-over-year to $248 million [1][10][13] - GAAP diluted EPS increased 36% year-over-year to $1.43, while non-GAAP diluted EPS rose 35% year-over-year to $1.72 [1][10][13] Financial Guidance - The company raised its 2025 financial guidance ranges for total revenue to $1,300 - $1,375 million, representing year-over-year growth of 28% - 35% [1][11] - Adjusted EBITDA guidance was raised to $885 - $935 million, indicating year-over-year growth of 40% - 48% [1][11] - Non-GAAP diluted EPS guidance was increased to $6.10 - $6.50, reflecting year-over-year growth of 44% - 54% [1][11] Corporate Developments - The company announced a transition plan for its Chief Financial Officer, Nicole LaBrosse, who will remain in her position until a successor is found or until March 30, 2026 [2][5] - Halozyme is set to acquire Elektrofi, a biopharmaceutical company, for $750 million in upfront consideration, with additional milestone payments contingent upon product regulatory approvals [8][11] - The acquisition is expected to close in the fourth quarter of 2025, pending regulatory review [8][11] Product and Market Expansion - The company achieved two new indication approvals this quarter, enhancing its growth catalysts [3][4] - The continued success of ENHANZE-enabled therapies, including DARZALEX SC, Phesgo, and VYVGART Hytrulo, underscores the strength of Halozyme's royalty-driven business model [3][4] - The company anticipates revenue growth contributions from additional launched ENHANZE products to increase in 2026 and beyond [3][4]